FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206149712> ?p ?o ?g. }

• W4206149712 endingPage "444" @default.
• W4206149712 startingPage "434" @default.
• W4206149712 abstract "The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventually always occurs. In osimertinib-resistant NSCLC, the emergence of a second molecular driver alteration (such as ALK, RET, FGFR3 fusions or BRAF, KRAS mutations) has been described. Whether those alterations and the activating EGFR mutations occur within a single cancer cell or in distinct cell populations is largely debated.Tumor sequencing was used to identify the acquired resistance mechanisms to osimertinib in the MATCH-R trial (NCT0251782). We implemented single-cell next-generation sequencing to investigate tumor heterogeneity on patient's frozen tissues in which multiple alterations have been identified. Patient-derived models, cell lines, and patient-derived xenografts were exposed to specific inhibitors to investigate combination treatment strategies.Among the 45 patients included in MATCH-R who progressed on osimertinib, 9 developed a second targetable alteration (n = 2 FGFR3-TACC3, n = 1 KIF5B-RET, n = 1 STRN-ALK fusions; n = 2 BRAFV600E, n = 1 KRASG12V, n = 1 KRASG12R, n = 1 KRASG12D mutations). Single-cell analysis revealed that the two driver alterations coexist within one single cancer cell in the four patients whose frozen samples were fully contributive. A high degree of heterogeneity within samples and sequential acquisitions of molecular events were highlighted. A combination treatment concomitantly targeting the two driver alterations was required on the corresponding patient-derived models to restore cell sensitivity, which was consistent with clinical data showing efficacy of brigatinib in the patient with ALK fusion after progression to osimertinib and crizotinib administered sequentially.Distinct molecular driver alterations at osimertinib resistance coexist with initial EGFR mutations in single cancer cells. The clonal evolution of cancer cell populations emphasized their heterogeneity leading to osimertinib relapse. Combining two targeted treatments is effective to achieve clinical benefit." @default.
• W4206149712 created "2022-01-26" @default.
• W4206149712 creator A5001814176 @default.
• W4206149712 creator A5002994486 @default.
• W4206149712 creator A5003964504 @default.
• W4206149712 creator A5007940997 @default.
• W4206149712 creator A5012092551 @default.
• W4206149712 creator A5019145125 @default.
• W4206149712 creator A5021624793 @default.
• W4206149712 creator A5023794502 @default.
• W4206149712 creator A5023804337 @default.
• W4206149712 creator A5025583232 @default.
• W4206149712 creator A5027991868 @default.
• W4206149712 creator A5028596081 @default.
• W4206149712 creator A5038206846 @default.
• W4206149712 creator A5039995907 @default.
• W4206149712 creator A5040811792 @default.
• W4206149712 creator A5042575799 @default.
• W4206149712 creator A5044818787 @default.
• W4206149712 creator A5065209996 @default.
• W4206149712 creator A5072110114 @default.
• W4206149712 creator A5072899659 @default.
• W4206149712 creator A5075099274 @default.
• W4206149712 creator A5087836238 @default.
• W4206149712 date "2022-04-01" @default.
• W4206149712 modified "2023-10-17" @default.
• W4206149712 title "Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients" @default.
• W4206149712 cites W1980497534 @default.
• W4206149712 cites W2065477010 @default.
• W4206149712 cites W2088669044 @default.
• W4206149712 cites W2154149901 @default.
• W4206149712 cites W2223496461 @default.
• W4206149712 cites W2356766777 @default.
• W4206149712 cites W2430050289 @default.
• W4206149712 cites W2586439898 @default.
• W4206149712 cites W2766679562 @default.
• W4206149712 cites W2770828094 @default.
• W4206149712 cites W2885289995 @default.
• W4206149712 cites W2891909134 @default.
• W4206149712 cites W2894066036 @default.
• W4206149712 cites W2898171786 @default.
• W4206149712 cites W2898359687 @default.
• W4206149712 cites W2951165708 @default.
• W4206149712 cites W2976334328 @default.
• W4206149712 cites W2978074062 @default.
• W4206149712 cites W2982467384 @default.
• W4206149712 cites W2990041408 @default.
• W4206149712 cites W3081505725 @default.
• W4206149712 cites W3084163391 @default.
• W4206149712 cites W3094182930 @default.
• W4206149712 cites W3125765158 @default.
• W4206149712 cites W3137204678 @default.
• W4206149712 cites W3154466284 @default.
• W4206149712 cites W3173935562 @default.
• W4206149712 doi "https://doi.org/10.1016/j.annonc.2022.01.004" @default.
• W4206149712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35066105" @default.
• W4206149712 hasPublicationYear "2022" @default.
• W4206149712 type Work @default.
• W4206149712 citedByCount "9" @default.
• W4206149712 countsByYear W42061497122022 @default.
• W4206149712 countsByYear W42061497122023 @default.
• W4206149712 crossrefType "journal-article" @default.
• W4206149712 hasAuthorship W4206149712A5001814176 @default.
• W4206149712 hasAuthorship W4206149712A5002994486 @default.
• W4206149712 hasAuthorship W4206149712A5003964504 @default.
• W4206149712 hasAuthorship W4206149712A5007940997 @default.
• W4206149712 hasAuthorship W4206149712A5012092551 @default.
• W4206149712 hasAuthorship W4206149712A5019145125 @default.
• W4206149712 hasAuthorship W4206149712A5021624793 @default.
• W4206149712 hasAuthorship W4206149712A5023794502 @default.
• W4206149712 hasAuthorship W4206149712A5023804337 @default.
• W4206149712 hasAuthorship W4206149712A5025583232 @default.
• W4206149712 hasAuthorship W4206149712A5027991868 @default.
• W4206149712 hasAuthorship W4206149712A5028596081 @default.
• W4206149712 hasAuthorship W4206149712A5038206846 @default.
• W4206149712 hasAuthorship W4206149712A5039995907 @default.
• W4206149712 hasAuthorship W4206149712A5040811792 @default.
• W4206149712 hasAuthorship W4206149712A5042575799 @default.
• W4206149712 hasAuthorship W4206149712A5044818787 @default.
• W4206149712 hasAuthorship W4206149712A5065209996 @default.
• W4206149712 hasAuthorship W4206149712A5072110114 @default.
• W4206149712 hasAuthorship W4206149712A5072899659 @default.
• W4206149712 hasAuthorship W4206149712A5075099274 @default.
• W4206149712 hasAuthorship W4206149712A5087836238 @default.
• W4206149712 hasBestOaLocation W42061497121 @default.
• W4206149712 hasConcept C104317684 @default.
• W4206149712 hasConcept C121608353 @default.
• W4206149712 hasConcept C126322002 @default.
• W4206149712 hasConcept C143998085 @default.
• W4206149712 hasConcept C2776232967 @default.
• W4206149712 hasConcept C2776256026 @default.
• W4206149712 hasConcept C2777626846 @default.
• W4206149712 hasConcept C2779422266 @default.
• W4206149712 hasConcept C2781187634 @default.
• W4206149712 hasConcept C501734568 @default.
• W4206149712 hasConcept C502942594 @default.
• W4206149712 hasConcept C526805850 @default.
• W4206149712 hasConcept C54355233 @default.

• next